Le Lézard
Classified in: Health
Subjects: SVY, WOM, AVO, MAT, DEI

Nearly 242,000 Women In Oregon Live In Contraceptive Deserts


WASHINGTON, Dec. 13, 2021 /PRNewswire-PRWeb/ -- According to data released by Power to Decide, an estimated 241,690 women living at or below 250% of the poverty level in Oregon live in contraceptive deserts, counties in which there is not reasonable access to a health center offering the full range of contraceptive methods. Currently, across the country more than 19 million U.S. women of low income live in contraceptive deserts.

"In Oregon, nearly 242,000 women must overcome significant barriers to access the contraception they need and deserve in order to decide if, when and under what circumstances to get pregnant and have a child," said Raegan McDonald-Mosley, MD, MPH, CEO of Power to Decide. "The challenge of covering costs associated with obtaining family planning services?such as transportation, child care and unpaid time off from work?may be too great a burden for those already struggling to make ends meet."

Additional data from Power to Decide show that 257,950 Oregonian women of reproductive age (13-44) in need of publicly funded contraception live in the 29 counties that were impacted by the Title X Family Planning Program "domestic gag rule" that was lifted on November 8, 2021, after more than two years of harm.

Despite these challenges, family planning providers have been making every effort to provide contraceptive services to patients across the state. In this challenging landscape, Oregon took proactive steps to partially alleviate the impact of the domestic gag rule and to expand access to contraception in various ways.

In addition to providing state funds to supplement the loss of federal Title X funds, Oregon has already expanded Medicaid to low-income adults, which helps decrease the percentage of uninsured women, and by extension, give them the contraceptive coverage they need to live healthy lives. In addition, Oregon has enacted state policies that allow pharmacists to prescribe contraception, require insurance to cover an extended supply of prescription contraceptives and protect insurance coverage of the full range of contraceptive methods.

More information about these policies can be found here. In addition, information about Oregon's telehealth policies relevant to contraceptive access can be found here.

Power to Decide is a private, non-partisan, non-profit organization that works to ensure all people?no matter who they are, where they live or what their economic status might be?have the power to decide if, when and under what circumstances to get pregnant and have a child. Please visit us at http://www.PowerToDecide.org or follow us on Facebook and Twitter.

Media Contact

Paloma Zuleta, Power to Decide, 202-812-4477, [email protected]

 

SOURCE Power to Decide


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: